Anatomic Pathology Market Poised for Remarkable Growth, Anticipating a 8.2% CAGR Leading to US$6.0 Billion Valuation by 2030, Persistence Market Research
23 janv. 2024 10h30 HE
|
Persistence Market Research
New York, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The global market for anatomic pathology market is projected to grow at a CAGR of 8.2%, increasing from US$3.5 billion in 2023 to US$6.0 billion by 2030....
Interpace Diagnostics Announces Pricing of $7.0 Million Public Offering of Common Stock
25 janv. 2019 06h00 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, N.J., Jan. 25, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (Nasdaq: IDXG) (“Interpace” or the “Company”) today announced the pricing of an underwritten public offering of...
Interpace Diagnostics Ranked as Top 10 Bioinformatics Solutions Provider
27 déc. 2018 06h55 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that CIO Applications, a publication focused on providing professionals with...
Newly Published Data from National Study Supports Interpace Diagnostics’ PancraGEN®
26 nov. 2018 06h55 HE
|
Interpace Diagnostics Group, Inc.
New Article in Peer-Reviewed Journal Highlights Important Role of PancraGEN® Testing PARSIPPANY, NJ, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)...
Interpace Diagnostics Announces New Coverage by Blue Cross Blue Shield for Thyroid Testing
07 nov. 2018 08h06 HE
|
Interpace Diagnostics Group, Inc.
The Federal Employee Health Benefit BCBS Program Adds Approximately 5.3 Million Covered Lives PARSIPPANY, NJ, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)...
Interpace Diagnostics Announces Participation at the DJCON18
24 oct. 2018 06h55 HE
|
Interpace Diagnostics Group, Inc.
Including Participation in the Panel on the Impact of AI and Bioinformatics in Healthcare PARSIPPANY, NJ, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)...
Interpace Diagnostics Supports Research Efforts of Pancreatic and Thyroid Cancer Patient Advocacy Groups
17 sept. 2018 08h30 HE
|
Interpace Diagnostics Group, Inc.
Interpace Employees Participate in Local Events in Support of Lustgarten Foundation for Pancreatic Cancer Research, Thyroid, Head and Neck Cancer Foundation, and Pancreatic Cancer Action Network ...
Interpace Diagnostics to Present at the 10th Annual Next Generation Dx Summit 2018
20 août 2018 16h30 HE
|
Interpace Diagnostics Group, Inc.
Discussing Methods for Securing Coverage and Reimbursement for Molecular Diagnostics PARSIPPANY, NJ, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)...
Interpace Diagnostics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement
31 juil. 2018 08h30 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, July 31, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that...